@article{2370c3b760d14a41ab2a6d29e8a1b579,
title = "AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma",
author = "Bowlus, {Christopher L.} and Lionel Arriv{\'e} and Annika Bergquist and Mark Deneau and Lisa Forman and Ilyas, {Sumera I.} and Lunsford, {Keri E.} and Mercedes Martinez and Gonzalo Sapisochin and Rachna Shroff and Tabibian, {James H.} and Assis, {David N.}",
note = "Funding Information: Dr. Bergquist advises Ipsen and received grants from Gilead. Dr. Bowlus received grants from Gilead, Bristol‐Myers Squibb, GlaxoSmithKline, Mirum, Genkyotex, Boston Scientific, Intercept, Target, Novartis, BiomX, CymaBay, Genfit, COUR and Pliant. Dr. Assis received grants from Gilead. Dr. Sapisochin consults and advises Integra. He consults and received grants from Roche. He consults for AstraZeneca, Novartis and Evidera. Dr. Forman received grants from Gilead, CymaBay and Mirum. Dr. Deneau consults for Gilead, HighTide and Mirum. Dr. Shroff advises and is on the speakers{\textquoteright} bureau for Servier. She advises and received grants from Merck and QED. She consults for SYROS. She advises AstraZeneca, Boehringer Ingelheim, Genentech, CAMI, Clovis, Incyte and Zymeworks. She received grants from Bayer, Bristol‐Myers Squibb, Exelixis, IMV, LOXO, Novocure, NUCANA, Pieris, Rafeal, Seagen and Taiho. Dr. Ilyas consults for AstraZeneca. Dr. Tabibian consults for Olympus. Funding Information: Funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. ",
year = "2023",
month = feb,
doi = "10.1002/hep.32771",
language = "English (US)",
volume = "77",
pages = "659--702",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",
}